{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:38:00Z","timestamp":1793741880120,"version":"4.6.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shanghai Natural Science Foundation Project","award":["19ZR1431400"],"award-info":[{"award-number":["19ZR1431400"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Arsenic trioxide (ATO) is highly effective in acute promyelocytic leukemia (APL) patients, but it fails to show satisfactory efficacy in other acute myeloid leukemia (AML) patients with non-APL subtypes. Different from the APL cells, most non-APL AML cells express low levels of the ATO transporter Aquaporin-9 (AQP9) protein, making them less sensitive to ATO treatment. Recently, we found that granulocyte colony stimulating factor (G-CSF) can upregulate the expression of AQP9. We hypothesized that the pretreatment with G-CSF may enhance the antitumor effect of ATO in non-APL AML cells. In addition, we aimed to elucidate the underlying mechanisms by which G-CSF upregulates the expression of AQP9.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Non-APL AML cell lines including THP-1 and HL-60 were pretreated with or without G-CSF (100\u00a0ng\/ml) for 24\u00a0h, followed by the treatment with ATO (2\u00a0\u03bcM) for 48\u00a0h. Cell morphology was observed under the microscope after Wright-Giemsa staining. Flow cytometry was performed to evaluate the cell apoptosis levels. The intracellular concentrations of ATO were determined by atomic fluorescence spectrometry. The mRNA and protein expression were respectively measured by quantitative reverse transcription PCR (RT-qPCR) and western blotting. Target genes were knocked down by transfection with small interfering RNA (siRNA), or overexpressed by transfection with overexpression plasmids. The cell line derived xenograft mouse model was established to confirm the results of the in vitro experiments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with using ATO alone, the combination of G-CSF with ATO induced the cell apoptosis more dramatically. G-CSF upregulated the expression of AQP9 and enhanced the intracellular concentrations of ATO in AML cells. When AQP9 was overexpressed, it markedly enhanced the cytotoxic activity of ATO. On the other hand, when AQP9 was knocked down, it profoundly attenuated the combinational effect. Moreover, we found that the upregulation of AQP9 by G-CSF depends on the transcription factor CCAAT enhancer binding protein beta (CEBPB). We also demonstrated that the combination of G-CSF and ATO significantly inhibited tumor growth in the xenograft mouse model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The combination of G-CSF and ATO may be a potential therapeutic strategy for AML patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12935-022-02613-y","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T09:07:04Z","timestamp":1652951224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["G-CSF upregulates the expression of aquaporin-9 through CEBPB to enhance the cytotoxic activity of arsenic trioxide to acute myeloid leukemia cells"],"prefix":"10.1186","volume":"22","author":[{"given":"Wanbin","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gelan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinpeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanbin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"issue":"12","key":"2613_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"key":"2613_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"issue":"4","key":"2613_CR3","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/leu.2014.216","volume":"29","author":"RB Walter","year":"2015","unstructured":"Walter RB, Estey EH. Management of older or unfit patients with acute myeloid leukemia. Leukemia. 2015;29(4):770\u20135.","journal-title":"Leukemia"},{"issue":"13","key":"2613_CR4","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1084\/jem.20131121","volume":"210","author":"GA Santos","year":"2013","unstructured":"Santos GA, Kats L, Pandolfi PP. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med. 2013;210(13):2793\u2013802.","journal-title":"J Exp Med"},{"issue":"5","key":"2613_CR5","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","volume":"111","author":"ZY Wang","year":"2008","unstructured":"Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111(5):2505\u201315.","journal-title":"Blood"},{"issue":"8","key":"2613_CR6","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/cncr.29852","volume":"122","author":"L Falchi","year":"2016","unstructured":"Falchi L, Verstovsek S, Ravandi-Kashani F, Kantarjian HM. The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: moving toward an effective oral, outpatient therapy. Cancer. 2016;122(8):1160\u20138.","journal-title":"Cancer"},{"issue":"2","key":"2613_CR7","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1182\/blood-2006-04-019588","volume":"109","author":"J Leung","year":"2007","unstructured":"Leung J, Pang A, Yuen WH, Kwong YL, Tse EW. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood. 2007;109(2):740\u20136.","journal-title":"Blood"},{"issue":"9","key":"2613_CR8","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1073\/pnas.0813280106","volume":"106","author":"J Hu","year":"2009","unstructured":"Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ, Chen Z. Long-term efficacy and safety of all-trans retinoic acid\/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2009;106(9):3342\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2613_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-015-0143-3","volume":"8","author":"D Chau","year":"2015","unstructured":"Chau D, Ng K, Chan TS, Cheng YY, Fong B, Tam S, Kwong YL, Tse E. Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9. J Hematol Oncol. 2015;8:46.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2613_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10735-015-9618-3","volume":"46","author":"X Wei","year":"2015","unstructured":"Wei X, Ren X, Jiang R, Li H, Gao F, Chen Y, Hou J, Liu X, Sun S, Yang M. Phosphorylation of p38 MAPK mediates aquaporin 9 expression in rat brains during permanent focal cerebral ischaemia. J Mol Histol. 2015;46(3):273\u201381.","journal-title":"J Mol Histol"},{"issue":"45","key":"2613_CR11","doi-asserted-by":"publisher","first-page":"44525","DOI":"10.1074\/jbc.M304368200","volume":"278","author":"H Arima","year":"2003","unstructured":"Arima H, Yamamoto N, Sobue K, Umenishi F, Tada T, Katsuya H, Asai K. Hyperosmolar mannitol simulates expression of aquaporins 4 and 9 through a p38 mitogen-activated protein kinase-dependent pathway in rat astrocytes. J Biol Chem. 2003;278(45):44525\u201334.","journal-title":"J Biol Chem"},{"issue":"4","key":"2613_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1074-7613(02)00424-7","volume":"17","author":"CL Semerad","year":"2002","unstructured":"Semerad CL, Liu F, Gregory AD, Stumpf K, Link DC. G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity. 2002;17(4):413\u201323.","journal-title":"Immunity"},{"issue":"4","key":"2613_CR13","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.4049\/jimmunol.1500861","volume":"195","author":"HM Mehta","year":"2015","unstructured":"Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in neutropenia. J Immunol. 2015;195(4):1341\u20139.","journal-title":"J Immunol"},{"issue":"8","key":"2613_CR14","first-page":"1191","volume":"7","author":"PA te Boekhorst","year":"1993","unstructured":"te Boekhorst PA, Lowenberg B, Vlastuin M, Sonneveld P. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia. 1993;7(8):1191\u20138.","journal-title":"Leukemia"},{"issue":"8","key":"2613_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2021.129929","volume":"1865","author":"QE Yang","year":"2021","unstructured":"Yang QE. Human cancer xenografts in immunocompromised mice provide an advanced genuine tumor model for research and drug development\u2014a revisit of murine models for human cancers. Biochim Biophys Acta Gen Subj. 2021;1865(8): 129929.","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"1","key":"2613_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.leu.2404021","volume":"20","author":"XF Yu","year":"2006","unstructured":"Yu XF, Yang C, Liang LH, Liu B, Zhou B, Li B, Han ZC. Inhibition of human leukemia xenograft in nude mice by adenovirus-mediated tissue inhibitor of metalloproteinase-3. Leukemia. 2006;20(1):1\u20138.","journal-title":"Leukemia"},{"key":"2613_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/978-3-540-79885-9_16","volume":"190","author":"H Bhattacharjee","year":"2009","unstructured":"Bhattacharjee H, Rosen BP, Mukhopadhyay R. Aquaglyceroporins and metalloid transport: implications in human diseases. Handb Exp Pharmacol. 2009;190:309\u201325.","journal-title":"Handb Exp Pharmacol"},{"issue":"6","key":"2613_CR18","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.3892\/or.2013.2388","volume":"29","author":"N Iriyama","year":"2013","unstructured":"Iriyama N, Yuan B, Yoshino Y, Hatta Y, Horikoshi A, Aizawa S, Takeuchi J, Toyoda H. Aquaporin 9, a promising predictor for the cytocidal effects of arsenic trioxide in acute promyelocytic leukemia cell lines and primary blasts. Oncol Rep. 2013;29(6):2362\u20138.","journal-title":"Oncol Rep"},{"issue":"1482","key":"2613_CR19","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1098\/rstb.2007.2026","volume":"362","author":"GB Zhou","year":"2007","unstructured":"Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci. 2007;362(1482):959\u201371.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"7","key":"2613_CR20","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2011.59","volume":"25","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, Hills RK, Hunter A, Milligan D, Kell J, Wheatley K, Yin J, McMullin MF, Cahalin P, Craig J, Bowen D, Russell N. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia. 2011;25(7):1122\u20137.","journal-title":"Leukemia"},{"issue":"3","key":"2613_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1046\/j.0007-1048.2001.03298.x","volume":"116","author":"MT Rojewski","year":"2002","unstructured":"Rojewski MT, Baldus C, Knauf W, Thiel E, Schrezenmeier H. Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. Br J Haematol. 2002;116(3):555\u201363.","journal-title":"Br J Haematol"},{"issue":"12","key":"2613_CR22","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1080\/10428190412331272686","volume":"45","author":"MT Rojewski","year":"2004","unstructured":"Rojewski MT, Korper S, Schrezenmeier H. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. Leuk Lymphoma. 2004;45(12):2387\u2013401.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2613_CR23","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1182\/blood.V96.4.1525","volume":"96","author":"GJ Roboz","year":"2000","unstructured":"Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP Jr, Rafii S. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood. 2000;96(4):1525\u201330.","journal-title":"Blood"},{"issue":"14","key":"2613_CR24","first-page":"3893","volume":"62","author":"WH Miller Jr","year":"2002","unstructured":"Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002;62(14):3893\u2013903.","journal-title":"Cancer Res"},{"issue":"9","key":"2613_CR25","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/ajh.22092","volume":"86","author":"JS Welch","year":"2011","unstructured":"Welch JS, Klco JM, Gao F, Procknow E, Uy GL, Stockerl-Goldstein KE, Abboud CN, Westervelt P, DiPersio JF, Hassan A, Cashen AF, Vij R. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. Am J Hematol. 2011;86(9):796\u2013800.","journal-title":"Am J Hematol"},{"key":"2613_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baw100","author":"AD Rouillard","year":"2016","unstructured":"Rouillard AD, Gundersen GW, Fernandez NF, Wang Z, Monteiro CD, McDermott MG, Ma\u2019ayan A. The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database. 2016. https:\/\/doi.org\/10.1093\/database\/baw100.","journal-title":"Database"},{"key":"2613_CR27","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3389\/fimmu.2019.01804","volume":"10","author":"W Wang","year":"2019","unstructured":"Wang W, Xia X, Mao L, Wang S. The CCAAT\/enhancer-binding protein family: its roles in MDSC expansion and function. Front Immunol. 2019;10:1804.","journal-title":"Front Immunol"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-022-02613-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-022-02613-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-022-02613-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T09:19:59Z","timestamp":1652951999000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-022-02613-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2613"],"URL":"https:\/\/doi.org\/10.1186\/s12935-022-02613-y","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"assertion":[{"value":"17 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of Ren Ji Hospital affiliated to Shanghai Jiao Tong University School of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"195"}}